PASADENA, Calif. --(BUSINESS WIRE)--Nov. 21, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: Piper Sandler 34 th Annual Healthcare Conference – November 30, 2022 Type: Fireside chat presentation
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 14, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 28, 2022 , at 4:30 p.m. ET to discuss its financial results for the 2022 fiscal year ended September 30, 2022 .
- Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease - Arrowhead retains rights to $400 million in development, regulatory, and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement PASADENA, Calif.
- ARO-APOC3 decreased triglycerides by 86%, and non-HDL-C by 45% while increasing HDL-C by 99% in patients with severe hypertriglyceridemia - ARO-ANG3 decreased triglycerides by 59%, LDL-C by 32%, and was associated with a relative reduction in liver fat fraction in patients with mixed dyslipidemia
PASADENA, Calif. --(BUSINESS WIRE)--Oct. 13, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 4, 2022 , the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to
- Company will host a virtual analyst and investor event on November 9, 2022 PASADENA, Calif. --(BUSINESS WIRE)--Oct. 11, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present interim clinical data from the ongoing SHASTA-2 Phase 2 study of ARO-APOC3 in patients
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 1, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: European Respiratory Society (ERS) International Congress 2022 – September 4-6, 2022 Title: Silencing MMP7
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 17, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce
- Conference Call and Webcast Today, August 4, 2022 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Aug. 4, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2022 . The company is hosting a conference call today,
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 20, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2022 , at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 third quarter ended June 30, 2022 .